Grosse Chance WKN 931506

Allen eine erfolgreiche Woche,und das es hier weiter so sachlich und ruhig bleibt
im Thread.

Gruss  

http://biz.yahoo.com/prnews/080513/cntu050.html?.v=1

Genesis Pharmaceuticals Announces Conference Call to Discuss Results for Third Quarter of FY 2008
Tuesday May 13, 9:20 am ET


LAIYANG, China, May 13 /Xinhua-PRNewswire-FirstCall/ -- Genesis Pharmaceuticals Enterprises, Inc. (OTC Bulletin Board: GTEC - News; ''Genesis'' or the ''Company''), a U.S. pharmaceutical company with its principal operations in the People's Republic of China, today announced that the Company will host a conference call at 10:00 a.m. Eastern on Friday, May 16, 2008 to discuss results for its third quarter ended March 31, 2008 of its fiscal year 2008.
ADVERTISEMENT


Conference Call

Genesis Pharmaceuticals management will host a conference call at 10:00 a.m. Eastern on Friday, May 16, 2008 to discuss financial results for the third quarter of its fiscal year 2008. The conference call will include Mr. Cao Wubo, Chairman and CEO, Mr. Haibo Xu, COO, and Ms Elsa Sung, CFO. To participate in this live conference call, please dial the following number five to ten minutes prior to the scheduled conference call time: (888) 482-0024. International callers should call (617) 801-9702. The Conference Passcode is 514 344 81. If you are unable to participate in the call at that time, replay of the conference call will be available from Friday, May 16 at 12:00 p.m. EST until Friday, May 30. To access the replay, call (888) 286- 8010. International callers should call (617) 801-6888. The Conference Passcode is 91325898.

About Genesis Pharmaceuticals Enterprises

Genesis Pharmaceuticals Enterprises, Inc. is a U.S. public company engaged in the research, development, production, marketing and sales of pharmaceutical products in the People's Republic of China. Its operations are located in Northeast China in an Economic Development Zone in Laiyang City, Shandong province. Genesis is a major pharmaceutical company in China producing both western and Chinese herbal-based medical drugs in tablet, capsule and granule form. The Company maintains a representative office in the U.S. For more information, refer to http://www.Genesis-China.net .  

termingerecht bis zum 15.Mai veröffentlicht werden!

ax

Das sieht fast nach morgen aus,reine Vermutung.
Auf jedenfall spätestens am Freitag.
Gruss  

Der Chart klebt irgendwie fest, obwohl bald News zu erwarten sind?

Bin ja echt gespannt was diese Woche laufen wird.

Hoffentlich gelingt uns ein Ausbruch nach oben.

 

MfG 

 

http://biz.yahoo.com/e/080515/gtec.ob10qsb.html  

http://www.sec.gov/Archives/edgar/data/1091164/...08-029408-index.htm  

sind die zahlen schlecht oder was?

lagen sie unter den erwartungen?

oder weshalb tut sich da drüben nix?

der kurs klebt an denn 33 us cents.

geht sogar hurz ins minus.

also ich weiß nich... ich bitte um analysen und meinungen. 

weiß da jemand mehr?? 

 

mfg 

 

REVENUES. During the nine months ended March 31, 2008, we had revenues of $71,259,900 as compared to revenues of $55,839,953 for the nine months ended March 31, 2007, an increase of $15,419,947 or approximately 27.61%. Our revenues include sales to related parties of $4,611,849 as compared to $2,963,871for the nine months ended March 31, 2007, an increase of $1,647,978 or approximately 55.60%. For the three months ended March 31, 2008, we had revenues of $28,100,283 as compared to revenues of $18,928,229 for the three months ended March 31, 2007, and increase of $9,172,054 or 48.46%. For the three months ended March 31, 2008, we had revenues from related party sales of $1,869,092 as compared to $455,580 for the three months ended March 31, 2007, an increase of $1,413,512 or 310.27%. The overall increase in total revenue in the third quarter and the nine months of fiscal 2008 was primarily attributable to the increase of sales volume of our best selling products: Clarithromycin sustained-release tablets and Itopride Hydrochloride Granules. Additionally, we released a new product, Baobaole chewable tablets in the second quarter of fiscal 2008. We believe that our sales will continue to grow as we continue strengthening our sales force, enhancing our brand name recognition and improving the quality of our products.

COST OF SALES. Cost of sales for the nine months ended March 31, 2008 increased $2,020,332 or 12.85%, from $ 15,724,047 for the nine months ended March 31, 2007 to $17,744,379 for the nine months ended March 31, 2008. Cost of sales for the three months ended March 31, 2008 increased $949,011 or 17.61% from $5,388,811 for the three months ended March 31, 2007 to $6,337,822 for the three months ended March 31, 2008. The decrease in cost of sales as a percentage of net revenues for the nine months ended March 31, 2008, approximately 24.90% as compared to the nine months ended March 31, 2007, approximately 28.16%, and the decrease in cost of sales as a percentage of net revenue for the three months ended March 31, 2008, approximately 22.55% as compared to the three months ended March 31, 2007 approximately 28.47%, was primarily attributable to our ability to better manage raw material purchase prices, the high margin on the new product Baobaole chewable tables, more sales being generated from products with higher profit margins and more efficient production.

GROSS PROFIT. Gross profit was $53,515,521 for the nine months ended March 31, 2008 as compared to $40,115,906 for the nine months ended March 31, 2007, representing gross margins of approximately 75.10% and 71.84%, respectively. Gross profit was $21,762,461 for the three months ended March 31, 2008 as compared to $13,539,418 for the three months ended March 31, 2007, representing gross margins of approximately 77.45% and 71.53%, respectively. The increase in our gross profits was mainly due to decrease in cost of sales as a percentage of net revenue as we better managed raw material purchase prices and our product sales mixture to generate more sales from products with higher profit margins.  

...wenn nicht noch heute (Stichwort: power hour), dann spätestens am morgigen Handelstag sollte es interessant werden im USA-Handel ...

ax

scheints aber wirklich nicht zu interessieren.

das hätte ich wirklich nicht gedacht.

besteht, denn die möglichkeit, dass sie es nicht mitbekommen, das die zahlen da sind?

 

mfg 

 

...
Additionally, we released a new product, Baobaole chewable tablets in the second quarter of fiscal 2008.

sten Passagen (die Finanzzahlen)

...mMn: es sieht seeeeeehr gut aus  [hier "steppt" bald der Bär]

! jeder sollte seine eigene Meinung bilden !

ax

ob die news grad eben rausgekommen sind.

eventuell besteht ja wirklich die möglichkeit, dass es die masse nicht erreicht hat.

aber es könnte auch sein, dass die irgendwie bereits im aktienkurs eingepreist war?

was denkt ihr?

 

mfg 

 

ist die Telefonkonferenz.
Glaub,da wird man noch Näheres erfahren.
bbb,halt uns bitte auf dem Laufenden.

Gruss  

in USA
...viele Filings/Zahlen zu lesen, da wird es etwas dauern, bis die "Rosinen" erkannt werden...

(Ruhe bewaren!)

ax

...ich ja echt mal gespannt auf morgen.

hatte mir heute mehr erhofft. nun, ja.

das volumen war heute sogar geringer wie gestern, warum auch immer?

wir werden sehen was morgen sache ist.

würde mich freuen, wenn wir uns weiter so gut austauschen können.

dann mal gut nacht... an alle.

 

MfG 

 

Es lässt sich alles nicht erzwingen,sons wär es zu einfach.
Die steigt,wenn Du nicht dran denkst.
Zumindest ist sie auch nicht gefallen,da können die Zahlen eigentlich nicht schlecht sein.

Gruss  

Posted by: Long-vestor  
In reply to: _bbb_  who wrote msg# 4186 Date:5/15/2008 2:57:23 PM
Post #of 4197

Comprehensive income from 2007 to 2008 up 118.36 %!!! Screaming growth!!
 

Posted by: _bbb_  
In reply to: _bbb_  who wrote msg# 4185 Date:5/15/2008 2:16:25 PM
Post #of 4197

LIQUIDITY AND CAPITAL RESOURCES


Our working capital position increased $14,761,942 to $30,759,382 at March 31, 2008 from $15,997,440 at June 30, 2007. This increase in working capital is primarily attributable to an increase in cash balance of $3.8 million, an increase in marketable equity securities of approximately $2.1 million, an increase in accounts receivable of approximately $8.8 million, an increase in accounts receivable-related parties of approximately $1.5 million, an increase in other receivables and other receivables of $0.3 million, an increase in advance to suppliers of $0.5 million, a decrease in short term bank loans of $1.9 million, a decrease in notes payable of $4.9 million, a decrease in other payable-related parties of $1 million, and a payment of dividend of $10.5 million, and offset by a decrease in restricted cash of $4.9 million, a decrease in other assets of 0.1 million , an increase in accounts payable of $1.4 million, an increase in other payable of $2.4 million, an increase in accrued liabilities of $0.3 million, an increase in liabilities assumed from reorganization of $1.4 million and an increase in taxes payable of $10.5 million.


Net cash provided in operating activities for the nine months ended March 31, 2008 was $17,697,452 as compared to net cash provided by operating activities of $4,283,404 for the nine months ended March 31, 2007. For the nine months ended March 31, 2008, net cash provided in operating activities was primarily attributable to income from continued operations of $13.2 million, increase in accounts payable of $1.2 million, increase in other payable of $2.1 million, increase in accrued liabilities of $0.3 million and increase in taxes payable of $10 million, offset by increase in our accounts receivable and accounts receivable-related parties of $8.6 million, increase in other receivable and other receivable-related parties of $0.3 million and increase in advance to suppliers balances of $0.5 million, and increase in liabilities assumed from reorganization of $1.2 million. For the nine months ended March 31, 2007, net cash provided by operating activities was attributable primarily to our net income of $7.4 million, decrease in inventories of $1.1 million, decrease in our other assets of $1.3 million and increase in our tax payable of $2 million and offset by increases in our accounts receivable and accounts receivable-related parties of $3.5 million, decrease in accounts payable of $2.3 million, and decrease in other payable and other payable-related parties of $ 1.9 million
 

REVENUES. During the nine months ended March 31, 2008, we had revenues of $71,259,900 as compared to revenues of $55,839,953 for the nine months ended March 31, 2007, an increase of $15,419,947 or approximately 27.61%. Our revenues include sales to related parties of $4,611,849 as compared to $2,963,871for the nine months ended March 31, 2007, an increase of $1,647,978 or approximately 55.60%. For the three months ended March 31, 2008, we had revenues of $28,100,283 as compared to revenues of $18,928,229 for the three months ended March 31, 2007, and increase of $9,172,054 or 48.46%. For the three months ended March 31, 2008, we had revenues from related party sales of $1,869,092 as compared to $455,580 for the three months ended March 31, 2007, an increase of $1,413,512 or 310.27%. The overall increase in total revenue in the third quarter and the nine months of fiscal 2008 was primarily attributable to the increase of sales volume of our best selling products: Clarithromycin sustained-release tablets and Itopride Hydrochloride Granules. Additionally, we released a new product, Baobaole chewable tablets in the second quarter of fiscal 2008. We believe that our sales will continue to grow as we continue strengthening our sales force, enhancing our brand name recognition and improving the quality of our products.

COST OF SALES. Cost of sales for the nine months ended March 31, 2008 increased $2,020,332 or 12.85%, from $ 15,724,047 for the nine months ended March 31, 2007 to $17,744,379 for the nine months ended March 31, 2008. Cost of sales for the three months ended March 31, 2008 increased $949,011 or 17.61% from $5,388,811 for the three months ended March 31, 2007 to $6,337,822 for the three months ended March 31, 2008. The decrease in cost of sales as a percentage of net revenues for the nine months ended March 31, 2008, approximately 24.90% as compared to the nine months ended March 31, 2007, approximately 28.16%, and the decrease in cost of sales as a percentage of net revenue for the three months ended March 31, 2008, approximately 22.55% as compared to the three months ended March 31, 2007 approximately 28.47%, was primarily attributable to our ability to better manage raw material purchase prices, the high margin on the new product Baobaole chewable tables, more sales being generated from products with higher profit margins and more efficient production.


GROSS PROFIT. Gross profit was $53,515,521 for the nine months ended March 31, 2008 as compared to $40,115,906 for the nine months ended March 31, 2007, representing gross margins of approximately 75.10% and 71.84%, respectively. Gross profit was $21,762,461 for the three months ended March 31, 2008 as compared to $13,539,418 for the three months ended March 31, 2007, representing gross margins of approximately 77.45% and 71.53%, respectively. The increase in our gross profits was mainly due to decrease in cost of sales as a percentage of net revenue as we better managed raw material purchase prices and our product sales mixture to generate more sales from products with higher profit margins.  

Posted by: Long-vestor  
In reply to: _bbb_  who wrote msg# 4183 Date:5/15/2008 2:15:01 PM
Post #of 4197

$28,100,283 quarter earnings, on target,, 9 months ended $71,259,900!!!!  
 

Der momentane Kurs von gtec ist ein Witz,ein schlechter.
Allerdings sind wir an der otc,also,da kann man es nicht so einfach erklären.
Wenn ich mich nicht bis zum Rand eingedeckt hätte,dann würd ich persönlich nachkaufen.
Die Zahlen werden noch besser in der Zukunft.
Der Grund für bessere Zahlen sind 4 Medikamente in der Genehmigungsphase,und einn glühendes Eisen in PhaseIII.
Irgentwann wird es honoriert im Kurs,kann morgen sein,....

Gute Nacht  

so sieht das aus ... :)
Habe nichts hinzuzufügen !!! :)

bbb  

http://biz.yahoo.com/prnews/080515/cnth114.html?.v=1
We have several new drugs that are still in various stages of approval from China's State Food and Drug Administration, and we believe that we will be able to introduce four new drugs in the near future."
So soll es sein.